(Q44492832)

English

In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

In vitro extreme drug resistance assay to taxanes or platinum compounds for the prediction of clinical outcomes in epithelial ovarian cancer: a prospective cohort study (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1 reference

based on heuristic

inferred from title

author name string

Hee Seung Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Tae Joong Kim

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Hyun Hoon Chung

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Jae Weon Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Byung Gie Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Noh Hyun Park

6

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Yong Sang Song

7

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Duk Soo Bae

8

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Soon Beom Kang

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

16 May 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Journal of Cancer Research and Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

135

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1513-1520

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

https://scigraph.springernature.com/pub.10.1007/s00432-009-0598-0

0 references

Cost-effective treatment of women with advanced ovarian cancer by cytoreductive surgery and chemotherapy directed by an in vitro assay for drug resistance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Breast cancer survival and in vitro tumor response in the extreme drug resistance assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medical decision making: a Bayesian approach to laboratory testing

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictive value of in vitro assessment of cytotoxic drug activity in advanced breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An in vitro short time-high dose drug exposure assay for predicting 5FU-resistance of colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second thoughts about second-look laparotomy in advanced ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of ovarian cancer survival: a population-based prospective study in Sweden

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extreme drug resistance is common after prior exposure to paclitaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Second-look versus second-nature

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical correlations with chemosensitivities measured in a rapid thymidine incorporation assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Individual chemosensitivity of in vitro proliferating mammary and ovarian carcinoma cells in comparison to clinical results of chemotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

In vitro assay-assisted treatment selection for women with breast or ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Testing chemotherapeutic combinations in the human tumor colony—forming assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid assay for evaluating the chemosensitivity of human tumors in soft agar culture

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extreme drug resistance assay and response to chemotherapy in patients with primary peritoneal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Investigation on marking method for phenomenon on regrowth drug resistance in relapsed acute myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19449027

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00432-009-0598-0

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44492832&oldid=2025696604"